<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00309231</url>
  </required_header>
  <id_info>
    <org_study_id>R-05-873</org_study_id>
    <secondary_id>11898</secondary_id>
    <nct_id>NCT00309231</nct_id>
  </id_info>
  <brief_title>Clinical Islet Transplantation Using the Edmonton Protocol</brief_title>
  <official_title>Clinical Islet Transplantation Using the Edmonton Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lawson Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>London Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Lawson Health Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to perform a series of islet transplants using the Edmonton&#xD;
      protocol. Patients with Type I Diabetes and glycemic lability, severe hypoglycemia or&#xD;
      hypoglycemic unawareness will undergo transplantation of purified pancreatic islets from&#xD;
      cadaveric donors into the portal vein, followed by steroid-free immunosuppression as per the&#xD;
      Edmonton protocol (IL-2 antibody induction, sirolimus, low dose tacrolimus-based&#xD;
      immunosuppression). The goals of the transplant are to improve glycemic control, stabilize&#xD;
      blood sugars and achieve insulin independence.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to document the outcomes of islet transplant at our centre while&#xD;
      replicating the Edmonton protocol. The Edmonton protocol, as described above, is currently&#xD;
      the standard clinical protocol for conducting clinical islet transplantation in selected&#xD;
      patients with type 1 diabetes. We propose to conduct a feasibility study to document the&#xD;
      availability and frequency of donor organs, test the process of islet isolation, assess the&#xD;
      implementation of procedures to transplant islets and administer immunosuppression, monitor&#xD;
      the complications of immunosuppression and document the success and safety of the transplant&#xD;
      procedure at our centre.&#xD;
&#xD;
      The outcomes we propose to document include: 1) the number of patients who achieve insulin&#xD;
      independence one year after completing the Edmonton protocol 2) the A1c value one year after&#xD;
      completing the Edmonton protocol 3) graft survival as measured by basal and stimulated&#xD;
      C-peptide levels 4) islet equivalents isolated from each donor organ and islet equivalents&#xD;
      per kg transplanted 5) complications of islet transplant and immunosuppressive therapy.&#xD;
&#xD;
      Eight patients who have had type 1 diabetes for more than 5 years will undergo islet&#xD;
      allotransplantation using the Edmonton protocol. It is expected that most patients will&#xD;
      require a minimum of two transplant procedures to receive enough islets to achieve insulin&#xD;
      independence. Procedures will follow published guidelines.&#xD;
&#xD;
      Pancreata will be isolated from brain-dead donors according to published protocols, including&#xD;
      the two-layer cold storage method. Islets will be cultured for up to 48 hours to facilitate&#xD;
      timing of the islet infusion.&#xD;
&#xD;
      Islets will be infused into the portal vein. Post transplant immunosuppression will consist&#xD;
      of the modified Edmonton protocol as outlined by Ryan et al including basiliximab induction&#xD;
      therapy, sirolimus and tacrolimus maintenance therapy, aspirin and enoxaparin&#xD;
      thromboprophylaxis, pneumocystis carinii prophylaxis with sulfamethoxazole/trimethoprim for 6&#xD;
      months and cytomegalovirus prophylaxis for 3 months if indicated. Insulin requirements will&#xD;
      be monitored closely after transplant. Serum glucose, glycosylated haemoglobin, serum&#xD;
      C-peptide, creatinine, and lipid concentrations will be monitored.&#xD;
&#xD;
      Patients will be seen in follow up every month initially and longer term every 3 to 6 months&#xD;
      as required. Glucose control, immunosuppressive levels and adverse events will be monitored&#xD;
      regularly. Patients will be monitored for complications of diabetes as per standard&#xD;
      guidelines. Tests of beta cell function (mixed meal Ensure test for glucose and C-peptide)&#xD;
      will be performed every 3 months initially and then every 6 months once stable.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    no funding&#xD;
  </why_stopped>
  <completion_date>January 2008</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Type 1 Diabetes</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Islet Allotransplantation</intervention_name>
    <description>Clinical islet transplantation using the Edmonton protocol, steroid free immunosuppression using sirolimus and tacrolimus and basilixumab induction therapy</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with type 1 diabetes of at least 5 years duration, with either severe hypoglycemia&#xD;
        with unawareness, or severe glycemic lability&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age 18-65 years&#xD;
&#xD;
          -  type 1 diabetes for at least 5 years&#xD;
&#xD;
          -  at least 1 of the following: a) frequent, severe hypoglycaemia b) hypoglycemic&#xD;
             unawareness* c) glycemic lability despite an optimal insulin regimen*, and failure of&#xD;
             intensive insulin therapy as judged by independent endocrinologist&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  obesity (BMI &gt;28&#xD;
&#xD;
          -  insulin requirements &gt; 0.7 U/kg/day&#xD;
&#xD;
          -  history of cancer (except basal or squamous skin cancer)&#xD;
&#xD;
          -  unstable, severe, or non-correctable cardiac disease&#xD;
&#xD;
          -  previous organ transplant&#xD;
&#xD;
          -  evidence of sensitization (PRA&gt;20%)&#xD;
&#xD;
          -  renal dysfunction (macroalbuminuria, renal dialysis)&#xD;
&#xD;
          -  untreated proliferative retinopathy&#xD;
&#xD;
          -  active infection, including hep C, hep B, HIV, TB&#xD;
&#xD;
          -  current cigarette smoking (6 months abstinence required) or substance abuse&#xD;
&#xD;
          -  indication for steroid medications (exception steroid inhalers, topical steroids)&#xD;
&#xD;
          -  indication for anticoagulation (exception aspirin)&#xD;
&#xD;
          -  pregnancy or desire for future pregnancy; breast-feeding&#xD;
&#xD;
          -  major psychiatric illness&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Wall, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Western Ontario, Canada</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>London Health Sciences Centre University Campus</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Ryan EA, Paty BW, Senior PA, Bigam D, Alfadhli E, Kneteman NM, Lakey JR, Shapiro AM. Five-year follow-up after clinical islet transplantation. Diabetes. 2005 Jul;54(7):2060-9.</citation>
    <PMID>15983207</PMID>
  </reference>
  <reference>
    <citation>Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, Warnock GL, Kneteman NM, Rajotte RV. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med. 2000 Jul 27;343(4):230-8.</citation>
    <PMID>10911004</PMID>
  </reference>
  <reference>
    <citation>Tsujimura T, Kuroda Y, Avila JG, Kin T, Oberholzer J, Shapiro AM, Lakey JR. Influence of pancreas preservation on human islet isolation outcomes: impact of the two-layer method. Transplantation. 2004 Jul 15;78(1):96-100.</citation>
    <PMID>15257045</PMID>
  </reference>
  <reference>
    <citation>Lakey JR, Burridge PW, Shapiro AM. Technical aspects of islet preparation and transplantation. Transpl Int. 2003 Sep;16(9):613-32. Epub 2003 Aug 19. Review.</citation>
    <PMID>12928769</PMID>
  </reference>
  <verification_date>June 2010</verification_date>
  <study_first_submitted>March 29, 2006</study_first_submitted>
  <study_first_submitted_qc>March 29, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2006</study_first_posted>
  <last_update_submitted>March 13, 2017</last_update_submitted>
  <last_update_submitted_qc>March 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2017</last_update_posted>
  <responsible_party>
    <name_title>Dr. William Wall</name_title>
    <organization>Lawson Health Research Institute</organization>
  </responsible_party>
  <keyword>diabetes mellitus</keyword>
  <keyword>islet transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

